Magle Chemoswed Holding


First North


Health Care

Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. In addition, it is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. The company was founded in 1944 and is based in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.



Länk till dynamisk (zoombar) graf för större skärmar

Nuvarande och kommande formation

MA Rank

Rulla till toppen